You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 16, 2024

ELESTAT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Elestat, and when can generic versions of Elestat launch?

Elestat is a drug marketed by Allergan and is included in one NDA.

The generic ingredient in ELESTAT is epinastine hydrochloride. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the epinastine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Elestat

A generic version of ELESTAT was approved as epinastine hydrochloride by BRECKENRIDGE on March 14th, 2011.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ELESTAT?
  • What are the global sales for ELESTAT?
  • What is Average Wholesale Price for ELESTAT?
Summary for ELESTAT
US Patents:0
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 107
Clinical Trials: 2
Patent Applications: 3,529
Drug Prices: Drug price information for ELESTAT
What excipients (inactive ingredients) are in ELESTAT?ELESTAT excipients list
DailyMed Link:ELESTAT at DailyMed
Drug patent expirations by year for ELESTAT
Drug Prices for ELESTAT

See drug prices for ELESTAT

Recent Clinical Trials for ELESTAT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Aston UniversityPhase 4
University of WorcesterPhase 4
Merck Sharp & Dohme Corp.Phase 4

See all ELESTAT clinical trials

Paragraph IV (Patent) Challenges for ELESTAT
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ELESTAT Ophthalmic Solution epinastine hydrochloride 0.05% 021565 1 2008-10-14

US Patents and Regulatory Information for ELESTAT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan ELESTAT epinastine hydrochloride SOLUTION/DROPS;OPHTHALMIC 021565-001 Oct 16, 2003 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ELESTAT

See the table below for patents covering ELESTAT around the world.

Country Patent Number Title Estimated Expiration
Taiwan I225401 ⤷  Sign Up
Austria 353218 ⤷  Sign Up
Israel 149501 SOLUTIONS CONTAINING EPINASTINE ⤷  Sign Up
Slovakia 287343 ⤷  Sign Up
China 1292752 ⤷  Sign Up
Denmark 1231920 ⤷  Sign Up
Saudi Arabia 1529 محاليل تحتوي على ابيناستين Epinastin ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.